Published in Eur Neuropsychopharmacol on November 22, 2008
A "genome-to-lead" approach for insecticide discovery: pharmacological characterization and screening of Aedes aegypti D(1)-like dopamine receptors. PLoS Negl Trop Dis (2012) 0.99
Ligand-enabled β-C-H arylation of α-amino acids using a simple and practical auxiliary. J Am Chem Soc (2015) 0.90
D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology (Berl) (2011) 0.89
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci (2013) 0.83
Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. Bioorg Med Chem (2010) 0.81
Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. Mol Pharmacol (2012) 0.80
Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology (Berl) (2012) 0.78
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Dopamine receptor signaling. J Recept Signal Transduct Res (2004) 3.47
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) (1994) 2.09
Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol (1998) 1.56
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect (1992) 1.47
Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther (1997) 1.23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem (2006) 1.22
Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci (2004) 1.19
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Mol Pharmacol (1996) 1.16
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem (1990) 1.14
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol (2003) 1.09
alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell (2004) 1.07
Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev (2009) 1.01
Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol (2001) 1.00
A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol Biochem Behav (2005) 1.00
What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther (2006) 1.00
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol (1991) 0.97
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol (2001) 0.95
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res (2007) 0.94
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther (1992) 0.91
Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs (2001) 0.91
Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res (2006) 0.90
Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse (1995) 0.87
D1 dopamine receptors. Int Rev Neurobiol (2001) 0.87
Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res (1994) 0.86
The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs (1995) 0.86
"Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology (1995) 0.85
Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson's disease. Ann N Y Acad Sci (2003) 0.82
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets (2006) 0.82
Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters. Psychopharmacology (Berl) (2006) 0.81
Clonidine-induced antinociception and locomotor hypoactivity are reduced by dexamethasone in mice. J Pharm Pharmacol (2001) 0.81
Three-dimensional pharmacology, a subject ranging from ignorance to overstatements. Pharmacol Toxicol (2003) 0.80
SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res (2001) 0.80
Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry (1990) 0.79
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther (2000) 0.79
Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurol Sci (2003) 0.79
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol (1988) 0.78
Racemic therapeutics--ethical and regulatory aspects. Eur J Clin Pharmacol (1991) 0.78
Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality (1993) 0.77
A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease. Neurology (1989) 0.77
A comparison of the effects of d-amphetamine and morphine upon the locomotor activity of mice treated with drugs which alter brain catecholamine content. J Pharmacol Exp Ther (1973) 0.77
Chiral discrimination and enantioselective analysis of drugs: an overview. J Pharm Sci (2007) 0.76
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol (2006) 2.02
Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange. Structure (2005) 1.98
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A (2008) 1.79
Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci (2013) 1.70
Team-based learning in US colleges and schools of pharmacy. Am J Pharm Educ (2013) 1.65
c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res (2002) 1.57
Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther (2008) 1.52
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat (2008) 1.42
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem (2008) 1.37
A point mutation to Galphai selectively blocks GoLoco motif binding: direct evidence for Galpha.GoLoco complexes in mitotic spindle dynamics. J Biol Chem (2008) 1.29
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther (2002) 1.25
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem (2006) 1.22
Regulatory properties of adenylate cyclases type 5 and 6: A progress report. Eur J Pharmacol (2006) 1.21
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol (2004) 1.19
Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene (2002) 1.19
Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther (2003) 1.17
EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (2012) 1.13
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem (2006) 1.13
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol (2005) 1.12
A high throughput, interactive imaging, bright-field wound healing assay. Cytometry A (2011) 1.10
A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett (2003) 1.09
Adenosine A(2A) receptors assemble into higher-order oligomers at the plasma membrane. FEBS Lett (2008) 1.09
WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) (2006) 1.07
Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos (2007) 1.06
Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal (2008) 1.06
Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. Hum Mol Genet (2009) 1.04
Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells. Mol Pharmacol (2008) 1.02
Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling. Mol Pharmacol (2009) 1.01
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation. Behav Pharmacol (2009) 1.01
Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav (2007) 1.00
Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene (2004) 1.00
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem (2003) 0.99
A "genome-to-lead" approach for insecticide discovery: pharmacological characterization and screening of Aedes aegypti D(1)-like dopamine receptors. PLoS Negl Trop Dis (2012) 0.99
Engineered zinc-binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter. Protein Sci (2006) 0.98
Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ (2002) 0.98
Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun (2007) 0.98
Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat (2007) 0.98
Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol (2007) 0.97
Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Mol Pharmacol (2004) 0.97
Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav (2007) 0.97
Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem (2005) 0.96
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem Neurosci (2012) 0.96
The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J (2006) 0.96
Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1. Biochem Biophys Res Commun (2005) 0.95
Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano (2014) 0.95
Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun (2006) 0.95
Novel regulatory properties of human type 9 adenylate cyclase. J Pharmacol Exp Ther (2004) 0.94
Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res (2010) 0.94
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res (2007) 0.94
Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther (2009) 0.93
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl) (2008) 0.93
Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues. ChemMedChem (2011) 0.92
Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J Pharmacol Exp Ther (2008) 0.92
New victims of current drug laws. Nat Rev Neurosci (2013) 0.92
A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des (2002) 0.91
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl) (2005) 0.91
Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res (2006) 0.90
Galphaq potentiation of adenylate cyclase type 9 activity through a Ca2+/calmodulin-dependent pathway. Biochem Pharmacol (2005) 0.90
Sensitization of adenylate cyclase: a general mechanism of neuroadaptation to persistent activation of Galpha(i/o)-coupled receptors? Life Sci (2003) 0.90
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem (2004) 0.89
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. J Med Chem (2003) 0.89
Genetic correlation between innate alcohol preference and fear-potentiated startle in selected mouse lines. Alcohol Clin Exp Res (2007) 0.89
Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. J Med Chem (2013) 0.89
Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J Pharmacol Exp Ther (2013) 0.88
ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes Cancer (2011) 0.88
secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res (2004) 0.88
Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem (2005) 0.88
Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem (2006) 0.87
Molecular and pharmacological characterization of two D(1)-like dopamine receptors in the Lyme disease vector, Ixodes scapularis. Insect Biochem Mol Biol (2011) 0.87
The intracellular II-III loops of Cav1.2 and Cav1.3 uncouple L-type voltage-gated Ca2+ channels from glucagon-like peptide-1 potentiation of insulin secretion in INS-1 cells via displacement from lipid rafts. J Pharmacol Exp Ther (2009) 0.86
Dexamethasone-induced Ras protein 1 negatively regulates protein kinase C delta: implications for adenylyl cyclase 2 signaling. Mol Pharmacol (2006) 0.85
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res (2007) 0.85
Sexual experience alters D1 receptor-mediated cyclic AMP production in the nucleus accumbens of female Syrian hamsters. Synapse (2004) 0.85
A bifunctional Galphai/Galphas modulatory peptide that attenuates adenylyl cyclase activity. FEBS Lett (2005) 0.85
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem (2008) 0.84
Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochem Pharmacol (2005) 0.83
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J Med Chem (2005) 0.83
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl) (2003) 0.83
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse (2002) 0.83
Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*. Growth Factors (2005) 0.83
Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. Cell Signal (2005) 0.83
Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res (2009) 0.82
Discovery of antagonists of tick dopamine receptors via chemical library screening and comparative pharmacological analyses. Insect Biochem Mol Biol (2012) 0.82
Palladium-catalyzed regio- and stereoselective γ-arylation of tertiary allylic amines: identification of potent adenylyl cyclase inhibitors. Org Lett (2015) 0.82